Crinetics Pharmaceuticals (CRNX) News Today $30.52 -3.13 (-9.30%) Closing price 04:00 PM EasternExtended Trading$30.48 -0.04 (-0.11%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Allostery Investments LP Acquires Shares of 9,700 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Allostery Investments LP bought a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,700 shares of the company's stock, valued at aMay 4 at 7:45 AM | marketbeat.comAcuta Capital Partners LLC Sells 8,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Acuta Capital Partners LLC decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,900 shares of the comMay 4 at 7:11 AM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Novo Holdings A SNovo Holdings A S decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 960,215 shares of the company's stock after selling 39,785 shares duMay 3 at 8:09 AM | marketbeat.comCrinetics Pharmaceuticals (CRNX) to Release Quarterly Earnings on ThursdayCrinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-crinetics-pharmaceuticals-inc-stock/)May 3 at 4:15 AM | marketbeat.comSchonfeld Strategic Advisors LLC Has $22.80 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Schonfeld Strategic Advisors LLC decreased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 445,946 shares of the company's stock after seMay 2, 2025 | marketbeat.com27,712 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Acquired by Aquatic Capital Management LLCAquatic Capital Management LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 27,712 shares of the company's stockMay 2, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $3.32 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Adage Capital Partners GP L.L.C. grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 62.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,000 shares of the comMay 2, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by First Trust Advisors LPFirst Trust Advisors LP lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 195,821 shares of the company's stock after sellingMay 1, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lowered by First Light Asset Management LLCFirst Light Asset Management LLC trimmed its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 885,453 shares of the company's stock after selling 58,158April 30, 2025 | marketbeat.comBoothbay Fund Management LLC Purchases 28,327 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Boothbay Fund Management LLC raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 25.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 137,752 shares of theApril 29, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Has $1.28 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Gilder Gagnon Howe & Co. LLC grew its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 98.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,044 shares of the company's stock after acquiring an aApril 29, 2025 | marketbeat.comMetLife Investment Management LLC Acquires 8,085 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)MetLife Investment Management LLC boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,020 shares of the company's stockApril 29, 2025 | marketbeat.comDecheng Capital LLC Acquires 10,000 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Decheng Capital LLC raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,958 shares of the company's stock aApril 28, 2025 | marketbeat.comLord Abbett & CO. LLC Lowers Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lord Abbett & CO. LLC trimmed its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 2.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 724,625 shares of the company's stock after selling 21,493 shares during the quartApril 28, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Lowers Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)T. Rowe Price Investment Management Inc. reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,002,882 sharesApril 28, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Buys 469,748 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Price T Rowe Associates Inc. MD raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 5,414,505 shares of the company's stock after acquiring an additional 469,748April 28, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc.Envestnet Asset Management Inc. grew its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 63,077 shares of the company's stock after purchasing an additiApril 27, 2025 | marketbeat.comHood River Capital Management LLC Raises Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Hood River Capital Management LLC raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 851,400 shares of the company's stockApril 25, 2025 | marketbeat.comBarclays PLC Decreases Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Barclays PLC cut its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 12.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,941 shares of the company's stock after selling 25,771 shares duriApril 25, 2025 | marketbeat.com25,900 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Acquired by Diadema Partners LPDiadema Partners LP bought a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 25,900 shares of the company's stock, valued at approximately $1,324,000. OtheApril 24, 2025 | marketbeat.comPeak6 LLC Purchases New Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Peak6 LLC acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,000 shares of the company's stock, valued at approximaApril 23, 2025 | marketbeat.comLegal & General Group Plc Has $4.55 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Legal & General Group Plc boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,939 shares of the company's stock after pApril 23, 2025 | marketbeat.comInvesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Invesco Ltd. lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 298,254 shares of the company's stock after buying an additional 42,9April 22, 2025 | marketbeat.comWells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Wells Fargo & Company MN grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 100,916 shares of the company's stock after acquiring an additional 16,025 shApril 22, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Russell Investments Group Ltd. reduced its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 56.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,200 shares of the company's stock after selling 43,501 shares duApril 21, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLCAffinity Asset Advisors LLC lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 460,000 shares of the company's stock after acApril 17, 2025 | marketbeat.comRep. Josh Gottheimer Sells Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockRepresentative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred iApril 15, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P.Alliancebernstein L.P. increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 101,720 shares of the company's stock afterApril 15, 2025 | marketbeat.comJPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)JPMorgan Chase & Co. reduced its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 269,543 shares of the companApril 14, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Moderate Buy" from AnalystsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and twelve have assigned a buyApril 14, 2025 | marketbeat.comFmr LLC Acquires 4,472,316 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fmr LLC raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 100.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,928,086 shares of the company's stock after purchasing anApril 12, 2025 | marketbeat.comGeode Capital Management LLC Boosts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Geode Capital Management LLC increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 13.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,098,841 sharApril 12, 2025 | marketbeat.comCrinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025April 11, 2025 | globenewswire.comCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2025 | globenewswire.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week Low - Here's What HappenedCrinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year Low - Here's WhyApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Has $2.72 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)ADAR1 Capital Management LLC lessened its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 39.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 53,125 shares of the company's stock after selling 35,300 shares during the quApril 9, 2025 | marketbeat.comSchroder Investment Management Group Makes New $1.49 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Schroder Investment Management Group purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 29,361 shares of the company's stock, valued atApril 8, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Cinctive Capital Management LPCinctive Capital Management LP trimmed its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 25.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,988 shares of the compApril 5, 2025 | marketbeat.comBryce Point Capital LLC Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Bryce Point Capital LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 22,686 shares of the company's stock, valued at approximately $1,1April 5, 2025 | marketbeat.comFranklin Resources Inc. Raises Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Franklin Resources Inc. lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,591,666 shares of the compApril 5, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 4.3% - Should You Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Time to Sell?April 3, 2025 | marketbeat.comWellington Management Group LLP Raises Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Wellington Management Group LLP boosted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 55.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,950,567 shares of the cApril 3, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company's stock after acquiring an adApril 3, 2025 | marketbeat.comCrinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFAApril 2, 2025 | seekingalpha.com16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company's stock, valued at approximately $818,000. A number ofApril 2, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year Low - Should You Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year Low - What's Next?April 1, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA decreased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 848,050 shares of the company's stock after selling 60April 1, 2025 | marketbeat.comAmerican Century Companies Inc. Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)American Century Companies Inc. lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 477,298 shares of the company's stoMarch 31, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Prudential Financial Inc.Prudential Financial Inc. increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 60.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 277,370 shares of the company's stock after purchasingMarch 29, 2025 | marketbeat.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼1.580.69▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼97▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today BridgeBio Pharma News Today Blueprint Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
